Laura J. Szewczyk

The top regional #healthcare and #biotech news for December 10th via the Big4Bio newsletters: San Diego: Sapient Hires Execs; Belharra Therapeutics Lays Off 40%; More on Kura Oncology, Inc. https://lnkd.in/g8nMwgHZ SF Bay: InCarda Therapeutics Names CEO; BioAge Labs Sees Stock Fall Over 70%; Biomemory Secures $18M; More from American Society of Hematology https://lnkd.in/gPGTjgwk Seattle: Talus Bio Welcomes Joyce; Sound Pharmaceuticals, Inc.'s Positive Phase 3 Results; Lyell Immunopharma's Trial Success for B-Cell Lymphoma https://lnkd.in/gFcDycKE Los Angeles: Kite Pharma's CAR T-Cell Therapy Breakthroughs; City of Hope's Innovative CLL Immunotherapy; Upcoming Events https://lnkd.in/gf8mSB7b Boston: Tasca Launches With $52M; Presentations at American Society of Hematology; Agios Pharmaceuticals' Stock Drops https://lnkd.in/g2k2HyAk Philadelphia: CorriXR Therapeutics Names CEO; Layoffs at Carisma Therapeutics; Better Catalytic Systems https://lnkd.in/ggjD49wp Capital Region: Alphyn Biologics, Inc. Granted First-in-Class Patent; TNF Pharmaceuticals, Inc. Reveals Results; Unlocking the Full Power of Transcriptomics https://lnkd.in/gWj-Wwui NYC: Ichnos Glenmark Innovation Unveils Trispecific Data; Dimension Raises $500M Fund; Protara Therapeutics' Public Offering; Woolsey Pharmaceuticals' Breakthrough Findings https://lnkd.in/gRzY_tDK

3

🌟 Clinical Tips from the 20th Annual California Cancer Consortium Conference 2024 🌟 Reflecting on key takeaways from this year's conference, where experts shared groundbreaking insights in cancer research and treatment: 🔬 Expansion Cohorts in Early Phase Clinical Trials: Valuable or Not? 📝 How to Submit a Clinical Letter of Intent (LOI) to NCI/CTEP 🫁 Advances in Limited and Extensive Stage Small Cell Lung Cancer 💡 New Biomarkers in Breast Cancer ⚡ Novel Targets in Hematologic Malignancies These sessions highlighted cutting-edge advancements and strategies shaping the future of oncology. Excited to see where these innovations will lead! #CaliforniaCancerConsortium #CancerResearch #ClinicalTrials #SmallCellLungCancer #BreastCancer #HematologicMalignancies #Oncology #ClinicalTips #MedicalInnovation #NCI #CancerCare Primo Lara Timothy Synold Jonathan Riess Paul Frankel Percy Ivy Tycel Phillips

7

The top regional #healthcare and #biotech news for January 10th via the Big4Bio newsletters: San Diego: Timberlyne Therapeutics Launches With $180M; Shoreline Biosciences, Inc. Cuts Staff; Belharra Therapeutics Hires CSO https://lnkd.in/gP4pb3wY SF Bay: Exec Hires; Ouro Medicines, Kardigan Launch; Layoffs at IGM Biosciences, Inc.; Biotech Ecosystem Venture Fund https://lnkd.in/gGbr4gvn Seattle: Transcarent, Accolade, Inc. $621M Deal; Slaoui & Phelan Join Achieve Life Sciences Board; AGC Biologics, Pandorum Technologies Collab https://lnkd.in/gAhtyWxk Los Angeles: Biocom California's New Directors; TAE Life Sciences & Kyoto University Breakthrough BNCT Results; UC Irvine's Bioluminescent RNA https://lnkd.in/gHWSiS92 Boston: Exec Changes; City Therapeutics, etherna, HARBOUR BIOMED Strike Deals; Restructuring at Repare Therapeutics, Intellia Therapeutics, Inc. https://lnkd.in/g_M8nQBp Philadelphia: Kardigan Launches; RhyGaze AG Raises $86M; How Fungi Make a Key Medicinal Molecule https://lnkd.in/g-ydsewW Capital Region: VERALOX Therapeutics to Acquire Nudge; Danaher Corporation, Innovaccer Partnership; Hot Investor Mandates; More on Vanda Pharmaceuticals NYC: Kardigan Launches; Pacira BioSciences, Inc.'s Five-year Plan; Pfizer Prospect Beats Incumbent; More on Johnson & Johnson https://lnkd.in/gP-cTPRZ

5

🌟 Best of #ASMS2024 🌟 Fintiede Solutions is thrilled to share the groundbreaking advancements unveiled by Evosep at the #ASMS2024 conference in Anaheim! Evosep continues to push the boundaries in the field of proteomics, introducing innovations that are set to transform research and clinical diagnostics. 🔬 Key Innovations Announced: Fully Automated Workflows: - Capable of processing over 500 plasma samples per day. - Maximizes efficiency and minimizes manual intervention. - Ideal for accelerating drug discovery and supporting large-scale translational research. - Reduces cost per sample and environmental impact. Whisper™ Zoom Methods: - Enhances scalability and sensitivity for detailed and accurate proteomic analyses. - Unlocks the ability to detect low-abundant proteins and identify novel biomarkers. - Facilitates deeper biological insights into disease pathways. Evosep Biolabs: Center of Excellence for High Throughput Proteomics: - Specializes in high-throughput proteomics with automated sample preparation. - Offers access to state-of-the-art LC-MS/MS workflows and expert assay development. - Provides scalable capacity for outsourcing proteomics research projects. 🏆 Impact and Vision: Evosep's innovations are designed to make clinical proteomics 100x more robust and 10x faster, revolutionizing the landscape of proteomics research. These advancements are particularly aimed at accelerating drug discovery and enhancing proteomics-based diagnostics, ultimately improving patient care. We are proud to be part of this journey and look forward to the incredible breakthroughs these technologies will enable in the near future. #Evosep #Proteomics #ASMS2024 #ScientificInnovation #DrugDiscovery #TranslationalResearch #Biomarkers #ClinicalDiagnostics #automation #whisper

2

SFBN Feed: BridgeBio gathers investors to launch rare disease-focused spinoff https://lnkd.in/gQEigHGr The company earlier this year spun out a cancer-focused company with $200 million. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #BayArea #SanFrancisco #Biotech #Lifescience #News

3

<!-- Content start --> South San Francisco, CA — July 3, 2024 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial (first-line) treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (nSq NSCLC), did not meet its primary endpoints of progression-free survival (PFS) at its primary analysis with a hazard ratio (HR) of 1.27 [95% CI: 1.02,1.57] and overall survival (OS) at its first interim analysis with a HR of 1.33 [95% CI: 1.02, 1.73], which was immature. The combination of tiragolumab plus Tecentriq and chemotherapy showed reduced efficacy in both PFS and OS compared to the comparator arm in the intent-to-treat population, which includes Phase II and Phase III cohorts. The overall safety profile remains consistent with the safety profile previously observed for the combination of tiragolumab plus Tecentriq and chemotherapy, and no new or unexpected findings were identified. Based on these results, patients and investigators will be unblinded and we intend to halt the study. A communication will be sent to the investigators and results will be shared with health authorities and subsequently presented at an upcoming medical meeting. “These results are disappointing as it was our hope that this combination might yield improved outcomes for people living with metastatic non-squamous lung cancer,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “We are thankful to all of the patients and healthcare professionals involved in the study, and we will leverage the learnings to inform our scientific understanding of the anti-TIGIT pathway and new avenues in cancer research.” Ongoing Phase III studies are investigating treatment settings and indications distinct from SKYSCRAPER-06. Based on today’s results, we will evaluate any relevant changes needed to the ongoing tiragolumab program. About SKYSCRAPER-06 study SKYSCRAPER-06 is a global Phase II/III, randomized, placebo-controlled and double-blinded study evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy as an initial (first-line) treatment versus pembrolizumab and chemotherapy in 542 people with non-squamous non-small cell lung cancer. Primary endpoints are overall survival (OS) and progression-free survival (PFS). About tiragolumab Tiragolumab is an investigational novel immune checkpoint inhibitor with an intact Fc region. Tiragolumab selectively binds to TIGIT, a novel inhibitory immune checkpoint which suppresses the immune response to cancer. Based on preclinical research, tiragolumab is thought to work as an immune amplifier with other cancer immunotherapies such as Tecentriq® (atezolizumab). The TIGIT pathway is distinct but

1

Candid Therapeutics, a new San Diego biotech bent on becoming a leader in the emerging T-cell engager space, has unwrapped three new research collaborations focusing on autoimmune diseases. Candid will partner with EpimAb Biotherapeutics, Inc. , Nona Biosciences and Ab Studio to beef up its pipeline of bispecific antibodies. https://lnkd.in/eU4ktbC6

9

SDBN Feed: Belharra Therapeutics sticks with lead programs, trims workforce by 40% https://lnkd.in/guTbHqbS San Diego startup Belharra Therapeutics, a biotech creating small molecule cancer and immunology medicines, has laid off 21 employees, Endpoints News has confirmed. Belharra, from the same team as Bayer-acquired Vividion, made the internal announcement [...]

6